Research progress on stem cell therapy for pathological skin scars

doi:10.3877/cma.j.issn.1673-9450.2019.05.013

Abstract

Abstract:

The current clinical treatment effect of hypertrophic scar is not satisfactory. Stem cells are expected to bring new ideas to treatment because of their ability to self-renew and differentiate. This article introduces some scar stem cells of different sources and their advantages and disadvantages, including various mesenchymal stem cells, human amniotic epithelial cells, embryonic stem cells and induced pluripotent stem cells etc. Besides, this article points out that the key points of breakthrough in stem cell therapy are the regulation of secreted protein, the proper using time of stem cells, the transmission and maintenance of stemness, and the selection of appropriate stem cell population for patients, etc. and provide a reference for the development of pathological scar stem cell therapy.

Key words: Keloid, Stem cells, Epithelial cells, Amnion, Hypertrophic Scar

Weishi Kong, Yongqiang Xiao, Yu Sun. Research progress on stem cell therapy for pathological skin scars[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2019, 14(05): 384-387.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2019.05.013

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2019/V14/I05/384

Figures/Tables 1

References 29

[1]	Berman B, Maderal A, Raphael B. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment[J]. Dermatol Surg, 2017, 43 Suppl 1: S3-S18.
[2]	Zhang C, Chen Y, Fu X. Sweat gland regeneration after burn injury: is stem cell therapy a new hope？[J]. Cytotherapy, 2015, 17(5): 526-535.
[3]	Li Q, Zhang C, Fu X. Will stem cells bring hope to pathological skin scar treatment？[J]. Cytotherapy, 2016, 18(8): 943-956.
[4]	Fu X, Li H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions[J]. Cell Tissue Res, 2009, 335(2): 317-321.
[5]	Wang J, Liao L, Wang S, et al. Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations[J]. Cytotherapy, 2013, 15(8): 893-904.
[6]	Ding L, Li X, Sun H, et al. Transplantation of bone marrow mesenchymal stem cells on collagen scaffolds for the functional regeneration of injured rat uterus[J]. Biomaterials, 2014, 35(18): 4888-4900.
[7]	Huang S, Wu Y, Gao D, et al. Paracrine action of mesenchymal stromal cells delivered by microspheres contributes to cutaneous wound healing and prevents scar formation in mice[J]. Cytotherapy, 2015, 17(7): 922-931.
[8]	Li Z, Wang H, Yang B, et al. Three-dimensional graphene foams loaded with bone marrow derived mesenchymal stem cells promote skin wound healing with reduced scarring[J]. Mater Sci Eng C Mater Biol Appl, 2015, 57: 181-188.
[9]	Jeong JH. Adipose stem cells and skin repair[J]. Curr Stem Cell Res Ther, 2010, 5(2): 137-140.
[10]	Liu J, Ren J, Su L, et al. Human adipose tissue-derived stem cells inhibit the activity of keloid fibroblasts and fibrosis in a keloid model by paracrine signaling[J]. Burns, 2018, 44(2): 370-385.
[11]	Wang L, Hu L, Zhou X, et al. Exosomes secreted by human adipose mesenchymal stem cells promote scarless cutaneous repair by regulating extracellular matrix remodelling[J]. Sci Rep, 2017, 7(1): 13321.
[12]	Zonari A, Martins TM, Paula AC, et al. Polyhydroxybutyrate-co-hydroxyvalerate structures loaded with adipose stem cells promote skin healing with reduced scarring[J]. Acta Biomater, 2015, 17: 170-181.
[13]	Kocaefe C, Balci D, Hayta BB, et al. Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair[J]. Stem Cell Rev Rep, 2010, 6(4): 512-522.
[14]	Peng J, Wang Y, Zhang L, et al. Human umbilical cord Wharton′s jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro[J]. Brain Res Bull, 2011, 84(3): 235-243.
[15]	Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton′s jelly of the human umbilical cord[J]. Stem Cell Rev Rep, 2013, 9(2): 226-240.
[16]	Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton′s jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity[J]. Stem Cells Dev, 2010, 19(4): 423-438.
[17]	Nekanti U, Rao VB, Bahirvani AG, et al. Long-term expansion and pluripotent marker array analysis of Wharton′s jelly-derived mesenchymal stem cells[J]. Stem Cells Dev, 2010, 19(1): 117-130.
[18]	Fan CG, Zhang QJ, Zhou JR. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord[J]. Stem Cell Rev Rep, 2011, 7(1): 195-207.
[19]	Batsali AK, Pontikoglou C, Koutroulakis D, et al. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton′s jelly and bone marrow-derived mesenchymal stem cells[J]. Stem Cell Res Ther, 2017, 8(1): 102.
[20]	Himal I, Goyal U, Ta M. Evaluating Wharton′s Jelly-Derived Mesenchymal Stem Cell′s Survival, Migration, and Expression of Wound Repair Markers under Conditions of Ischemia-Like Stress[J]. Stem Cells Int, 2017, 2017: 5259849.
[21]	Bakhtyar N, Jeschke MG, Herer E, et al. Exosomes from acellular Wharton′s jelly of the human umbilical cord promotes skin wound healing[J]. Stem Cell Res Ther, 2018, 9(1): 193.
[22]	Zheng Y, Zheng S, Fan X, et al. Amniotic Epithelial Cells Accelerate Diabetic Wound Healing by Modulating Inflammation and Promoting Neovascularization[J]. Stem Cells Int, 2018, 2018: 1082076.
[23]	Zhao B, Zhang Y, Han S, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation[J]. J Mol Histol, 2017, 48(2): 121-132.
[24]	Zhao B, Liu JQ, Yang C, et al. Human amniotic epithelial cells attenuate TGF-β1-induced human dermal fibroblast transformation to myofibroblasts via TGF-β1/Smad3 pathway[J]. Cytotherapy, 2016, 18(8): 1012-1024.
[25]	Troy TC, Turksen K. Using high-throughput immunoblotting to identify proteins involved in the differentiation of ES cells along the hair follicle lineage in vitro[J]. Stem Cell Rev Rep, 2011, 7(4): 1041-1045.
[26]	Dreymueller D, Denecke B, Ludwig A, et al. Embryonic stem cell-derived M2-like macrophages delay cutaneous wound healing[J]. Wound Repair Regen, 2013, 21(1): 44-54.
[27]	Liu SP, Fu RH, Huang YC, et al. Induced pluripotent stem (iPS) cell research overview[J]. Cell Transplant, 2011, 20(1): 15-19.
[28]	Ren Y, Deng CL, Wan WD, et al. Suppressive effects of induced pluripotent stem cell-conditioned medium on in vitro hypertrophic scarring fibroblast activation[J]. Mol Med Rep, 2015, 11(4): 2471-2476.
[29]	Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds[J]. Stem Cell Res Ther, 2010, 1(4): 30.

干细胞类型	优势	不足
BMMSC	治疗病理性瘢痕的最佳来源和其它干细胞疗法的衡量标准，可高度增殖、自我更新^[4]	移植效果尚不稳定^[6,7,8]
ASC	来源广泛，容易获取，可高度增殖、自我更新^[9]	安全性有待进一步评估^[9]
UCB-MSC和WJ-MSC	来源于脐带废组织，相比BMMSC和ASC更具原始性^[19]	UCB-MSC相对分离困难^[18]
hAEC	具有免疫耐受、低免疫原性、非致瘤性、旁分泌功能等优势^[22,23,24]	不具自我更新能力，易发生上皮-间质转化^[22,23,24]
ESC	可无限增殖、自我更新，具有多向分化的潜能^[25]	来源于人类胚胎，存在伦理学争议^[25]
iPSC	治疗瘢痕作用同ESC^[27]	容易发生基因变化^[27]

干细胞类型	优势	不足
BMMSC	治疗病理性瘢痕的最佳来源和其它干细胞疗法的衡量标准，可高度增殖、自我更新^[4]	移植效果尚不稳定^[6,7,8]
ASC	来源广泛，容易获取，可高度增殖、自我更新^[9]	安全性有待进一步评估^[9]
UCB-MSC和WJ-MSC	来源于脐带废组织，相比BMMSC和ASC更具原始性^[19]	UCB-MSC相对分离困难^[18]
hAEC	具有免疫耐受、低免疫原性、非致瘤性、旁分泌功能等优势^[22,23,24]	不具自我更新能力，易发生上皮-间质转化^[22,23,24]
ESC	可无限增殖、自我更新，具有多向分化的潜能^[25]	来源于人类胚胎，存在伦理学争议^[25]
iPSC	治疗瘢痕作用同ESC^[27]	容易发生基因变化^[27]

Please choose a citation manager

Content to export